Prof. T.D. Zvyagintseva, A.V. Yaroshenko
Kharkiv medical academy of postgraduation education
Article presents review of new biological methods for the diagnosis of IBD. The problem of late diagnosis of IBD remains relevant because of increased frequency of adverse consequences of the disease by increasing the length of the period when patients do not receive adequate treatment. Well-known today are biological markers of inflammatory bowel disease, which are determined by non-invasive methods and are often an alternative to colonoscopy. C-reactive protein (CRP) is recognized as one of the most important proteins in the acute inflammation phase. Changes in the content of fecal calprotectin (FCP) in patients with IBD due to the clinical activity of inflammatory bowel disease and are closely related to the extent of colon damage. New fecal biomarkers such as Defensin, Myeloperoxidase, Pyruvate kinase, Lipocalin and others are a sensitive tool for screening for inflammation of the intestine and an indicator of its severity. New fecal markers may help improve the diagnosis, evaluation, and clinical outcomes of treatment of patients with inflammatory bowel disease.
https://dx.doi.org/10.15407/internalmed2021.01.103
Cite:
1. Звягінцева, Т.Д., Ярошенко, А.В. Біологічна діагностика запальних захворювань кишечника: поточні ідеї і майбутні досягнення // Східноєвропейський журнал внутрішньої та сімейної медицини. – 2021. – №1. – С. 103-108. doi: 10.15407/internalmed2021.01.103
2. Zvyagintseva TD, Yaroshenko AV. [Biological diagnosis of inflammatory bowel disease: current ideas and future achievements]. Shidnoevr. z. vnutr. simejnoi med. 2021;1:103-108. Ukrainian. doi: 10.15407/internalmed2021.01.103
References:
1. Dolhikh TI. Fekalnyi kalprotektin – neinvazyvnyi byomarkerom zapalnoho protsesu kyshechnyka. Laboratoriia. Spetsvypusk. 2018;2: 8-12. Ukrainian
2. Lutseva AA, Kokhanov AV. Voronkova MYu. Rivni laktoferynu v syrovattsi krovi i fekalnykh ekstrak pry deiakykh zapalnykh zakhvoriuvanniakh kyshechnyka. Suchasni problemy nauky ta osvity. 2019;1. Ukrainian
3. Dai C, Jiang M, Sun M, Cao Q. Fecal Lactoferrin for Assessment of Inflammatory Bowel Disease Activity. Journal of Clinical Gastroenterology. 2019;54(6):545-553. http://dx.doi.org/10.1097/mcg.0000000000001212
https://doi.org/10.1097/MCG.0000000000001212
4. SIPPONEN T, KÄRKKÄINEN P, SAVILAHTI E, KOLHO K, NUUTINEN H, TURUNEN U, FÄRKKILÄ M. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn’s disease and histological findings. Alimentary Pharmacology & Therapeutics. 2008;28(10):1221-1229. http://dx.doi.org/10.1111/j.1365-2036.2008.03835.x
https://doi.org/10.1111/j.1365-2036.2008.03835.x
5. D’Incà R, Dal Pont E, Di Leo V, Ferronato A, Fries W, Vettorato M, Martines D, Sturniolo G. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. International Journal of Colorectal Disease. 2006;22(4):429-437. http://dx.doi.org/10.1007/s00384-006-0159-9
https://doi.org/10.1007/s00384-006-0159-9
6. Fengming Y, Jianbing W. Biomarkers of Inflammatory Bowel Disease. Disease Markers. 2014;2014:1-11. http://dx.doi.org/10.1155/2014/710915
https://doi.org/10.1155/2014/710915
7. Yamamoto-Furusho J, Fonseca-Camarillo G. Genetic Markers Associated with Clinical Outcomes in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2015;21(11):2683-2695. http://dx.doi.org/10.1097/mib.0000000000000500
https://doi.org/10.1097/MIB.0000000000000500
8. Norouzinia M, Chaleshi V, Alizadeh AHM, Zali MR. Biomarkers in inflammatory bowel diseases: insight into diagnosis, prognosis and treatment. Gastroenterol. Hepatol. Bed Bench. 2017; 10(3):155-167.
9. Treton X, Bouhnik Y, Mary J, Colombel J, Duclos B, Soule J, Lerebours E, Cosnes J, Lemann M. Azathioprine Withdrawal in Patients With Crohn’s Disease Maintained on Prolonged Remission: A High Risk of Relapse. Clinical Gastroenterology and Hepatology. 2009;7(1):80-85. http://dx.doi.org/10.1016/j.cgh.2008.08.028
https://doi.org/10.1016/j.cgh.2008.08.028
10. Lémann M, Mary J, Colombel J, Duclos B, Soule J, Lerebours E, Modigliani R, Bouhnik Y. A Randomized, Double-Blind, Controlled Withdrawal Trial in Crohn’s Disease Patients in Long-term Remission on Azathioprine. Gastroenterology. 2005;128(7):1812-1818. http://dx.doi.org/10.1053/j.gastro.2005.03.031
https://doi.org/10.1053/j.gastro.2005.03.031
11. Jones J, Loftus E, Panaccione R, Chen L, Peterson S, Mcconnell J, Baudhuin L, Hanson K, Feagan B, Harmsen S, Zinsmeister A, Helou E, Sandborn W. Relationships Between Disease Activity and Serum and Fecal Biomarkers in Patients With Crohn’s Disease. Clinical Gastroenterology and Hepatology. 2008;6(11):1218-1224. http://dx.doi.org/10.1016/j.cgh.2008.06.010
https://doi.org/10.1016/j.cgh.2008.06.010
12. Cioffi M. Laboratory markers in ulcerative colitis: Current insights and future advances. World Journal of Gastrointestinal Pathophysiology. 2015;6(1):13. http://dx.doi.org/10.4291/wjgp.v6.i1.13
https://doi.org/10.4291/wjgp.v6.i1.13
13. Derkacz A, Olczyk P, Komosinska-Vassev K. Diagnostic Markers for Nonspecific Inflammatory Bowel Diseases. Disease Markers. 2018;2018:1-16. http://dx.doi.org/10.1155/2018/7451946
https://doi.org/10.1155/2018/7451946
14. Wright E. Calprotectin or Lactoferrin: Do They Help. Digestive Diseases. 2016;34(1-2):98-104. http://dx.doi.org/10.1159/000442935
https://doi.org/10.1159/000442935
15. Lin J, Chen J, Zuo J, Yu A, Xiao Z, Deng F, Nie B, Jiang B. Meta-analysis. Inflammatory Bowel Diseases. 2014;20(8):1407-1415. http://dx.doi.org/10.1097/mib.0000000000000057
https://doi.org/10.1097/MIB.0000000000000057
16. Duvoisin G, Lopez R, Day A, Lemberg D, Gearry R, Leach S. Novel Biomarkers and the Future Potential of Biomarkers in Inflammatory Bowel Disease. Mediators of Inflammation. 2017;2017:1-9. http://dx.doi.org/10.1155/2017/1936315
https://doi.org/10.1155/2017/1936315
17. Di Ruscio M, Vernia F, Ciccone A, Frieri G, Latella G. Surrogate Fecal Biomarkers in Inflammatory Bowel Disease: Rivals or Complementary Tools of Fecal Calprotectin?. Inflammatory Bowel Diseases. 2017;24(1):78-92. http://dx.doi.org/10.1093/ibd/izx011
https://doi.org/10.1093/ibd/izx011
18. Duvoisin G, Lopez R, Day A, Lemberg D, Gearry R, Leach S. Novel Biomarkers and the Future Potential of Biomarkers in Inflammatory Bowel Disease. Mediators of Inflammation. 2017;2017:1-9. http://dx.doi.org/10.1155/2017/1936315
https://doi.org/10.1155/2017/1936315
19. Bahgat M. Bio-Markers of Inflammatory Bowel Disease: Past, Present, and Future. Austin Journal of Gastroenterology. 2017;:. http://dx.doi.org/10.26420/austinjgastroenterol.2017.1082
https://doi.org/10.26420/AustinJGastroenterol.2017.1082
20. Stallhofer J, Friedrich M, Konrad-Zerna A, Wetzke M, Lohse P, Glas J, Tillack-Schreiber C, Schnitzler F, Beigel F, Brand S. Lipocalin-2 Is a Disease Activity Marker in Inflammatory Bowel Disease Regulated by IL-17A, IL-22, and TNF-α and Modulated by IL23R Genotype Status. Inflammatory Bowel Diseases. 2015;:1. http://dx.doi.org/10.1097/mib.0000000000000515
https://doi.org/10.1097/MIB.0000000000000515
21. Thorsvik S, Damås J, Granlund A, Flo T, Østvik A, Sandvik A. P-110 YI Fecal Neutrophil Gelatinase-Associated Lipocalin (NGAL) Is a Promising Biomarker for Inflammatory Bowel Disease and NGAL Is Expressed in Paneth Cells. Inflammatory Bowel Diseases. 2016;22:S44. http://dx.doi.org/10.1097/01.mib.0000480215.61802.bb
https://doi.org/10.1097/01.MIB.0000480215.61802.bb
22. Norouzinia M, Chaleshi V, Alizadeh A. Biomarkers in inflammatory bowel diseases: insight into diagnosis, prognosis and treatment. Gastroenterol Hepatol Bed Bench. 2017;10 (3):155-167.
23. Galgut B, Lemberg D, Day A, Leach S. The Value of Fecal Markers in Predicting Relapse in Inflammatory Bowel Diseases. Frontiers in Pediatrics. 2018;5:292. http://dx.doi.org/10.3389/fped.2017.00292
https://doi.org/10.3389/fped.2017.00292
24. Gao Q, Meijer M, Schlüter U, van Hogezand R, van der Zon J, van den Berg M, van Duijn W, Lamers C, Verspaget H. Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and -9 in Crohnʼs disease. Inflammatory Bowel Diseases. 2007;13(6):693-702. http://dx.doi.org/10.1002/ibd.20100
https://doi.org/10.1002/ibd.20100
25. SIDHU R, WILSON P, WRIGHT A, YAU C, D’CRUZ F, FOYE L, MORLEY S, LOBO A, MCALINDON M, SANDERS D. Faecal lactoferrin – a novel test to differentiate between the irritable and inflamed bowel?. Alimentary Pharmacology & Therapeutics. 2010;31(12):1365-1370. http://dx.doi.org/10.1111/j.1365-2036.2010.04306.x
https://doi.org/10.1111/j.1365-2036.2010.04306.x